BioCardia, Inc. announced the election of Mr. Marvin Slosman to its Board of Directors.
Dr. Richard Krasno completed his term and departed the Board.
Mr. Slosman brings deep expertise in interventional cardiology and commercialization of breakthrough technologies.
New Board Director
Mr. Marvin Slosman brings expertise in regulatory pathways and global market expansion.
Outgoing Director
Dr. Richard Krasno guided the Company through key milestones and clinical evidence development.
Company Mission
BioCardia is focused on advancing therapies to treat cardiovascular disease.
- The addition of Mr. Slosman enhances BioCardia's board with his experience in commercial growth and regulatory pathways.
- Dr. Krasno's contributions to key milestones and governance structure have been instrumental for BioCardia's development.
BioCardia expresses gratitude to Dr. Richard Krasno for his service and welcomes Mr. Marvin Slosman to the Board, enhancing the Company's expertise.